Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Pyridam Farma Tbk's quarterly common stock
increased
from Sep. 2025 (Rp1,123,669 Mil) to Dec. 2025 (Rp1,123,669 Mil) and
increased
from Dec. 2025 (Rp1,123,669 Mil) to Mar. 2026 (Rp1,123,669 Mil).
PT Pyridam Farma Tbk's annual common stock
increased
from Dec. 2023 (Rp53,508 Mil) to Dec. 2024 (Rp1,123,668 Mil) and
increased
from Dec. 2024 (Rp1,123,668 Mil) to Dec. 2025 (Rp1,123,669 Mil).
PT Pyridam Farma Tbk Common Stock Historical Data
* Premium members only.
The historical data trend for PT Pyridam Farma Tbk's Common Stock can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Pyridam Farma Tbk (ISX:PYFA) has a Common Stock of Rp1,123,669 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on PT Pyridam Farma Tbk and its competitors.
Is PT Pyridam Farma Tbk's Common Stock too high?
PT Pyridam Farma Tbk's current Common Stock is Rp1,123,669 Mil. Overall, PT Pyridam Farma Tbk has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's Common Stock compare to ZTS and UTHR?
PT Pyridam Farma Tbk's Common Stock of Rp1,123,669 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on PT Pyridam Farma Tbk and its competitors. PT Pyridam Farma Tbk's current Common Stock is Rp1,123,669 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Fairly Valued. The stock's GF Value™ is Rp211.99, compared to a current price of Rp206.00 — trading 2.8% below its estimated fair value. The current Common Stock is Rp1,123,669 Mil. PT Pyridam Farma Tbk's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current Common Stock is Rp1,123,669 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be undervalued.
The current stock price of Rp206.00 is trading 2.8% below its estimated GF Value™ of Rp211.99.
GuruFocus considers PT Pyridam Farma Tbk to be Fairly Valued.
Key valuation signals for ISX:PYFA:
Common Stock: Rp1,123,669 Mil
GF Value™: Rp211.99 vs. price of Rp206.00 (2.8% below fair value)
No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
67GF Score
Get the complete analysis for ISX:PYFA
Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PYFA has been successfully added to your 
